UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reinforcement of hydrated portland cement with high molecular mass water-soluble polymers

Journal of materials science, 2007-07, Vol.42 (13), p.4858-4869

2007

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

The lancet HIV, 2020-01, Vol.7 (1), p.e16-e26

2020

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

The lancet HIV, 2018-05, Vol.5 (5), p.e211-e220

2018

Volltextzugriff (PDF)

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co‐infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End‐Stage Liver Disease as Compared to HCV Mono‐infected Patients

Hepatology (Baltimore, Md.), 2019-09, Vol.70 (3), p.939-954

2019

Volltextzugriff (PDF)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

AIDS (London), 2009-11, Vol.23 (17), p.2289-2300

2009

Volltextzugriff (PDF)

Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers

The Journal of infectious diseases, 2021-11, Vol.224 (9), p.1570-1580

2021

Volltextzugriff (PDF)

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

The lancet HIV, 2024-02, Vol.11 (2), p.e75-e85

2024

Volltextzugriff (PDF)

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

The lancet HIV, 2024-03, Vol.11 (3), p.e156-e166

2024

Volltextzugriff (PDF)

Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 Study

Clinical infectious diseases, 2002-05, Vol.34 (9), p.1243-1250

2002

Volltextzugriff (PDF)

Prognostic factors of survival in HIV/HCV co‐infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort

Liver international, 2019-01, Vol.39 (1), p.136-146

2019

Volltextzugriff (PDF)

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31-39

2011

Volltextzugriff (PDF)

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial

AIDS (London), 2012-09, Vol.26 (15), p.1895-1905

2012

Volltextzugriff (PDF)

Toxoplasmic Encephalitis in Patients with the Acquired Immunodeficiency Syndrome

The New England journal of medicine, 1993-09, Vol.329 (14), p.995-1000

1993

Volltextzugriff (PDF)

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients

AIDS (London), 1996-11, Vol.10 (13), p.1521-1527

1996

Volltextzugriff (PDF)

Increased Risk of Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients with Pyrimethamine-Related Rash

Clinical infectious diseases, 1997-03, Vol.24 (3), p.396-402

1997

Volltextzugriff (PDF)

Pyrimethamine for Primary Prophylaxis of Toxoplasmic Encephalitis in Patients with Human Immunodeficiency Virus Infection: A Double-Blind, Randomized Trial

The Journal of infectious diseases, 1996-01, Vol.173 (1), p.91-97

1996

Volltextzugriff (PDF)

Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients

Controlled clinical trials, 1998, Vol.19 (3), p.233-248

1998

Volltextzugriff (PDF)

Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039

Clinical infectious diseases, 2002-05, Vol.34 (9), p.1243

2002

Volltextzugriff (PDF)

Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data

Controlled clinical trials, 1998-06, Vol.19 (3), p.233-248

1998

Volltextzugriff (PDF)

La co-infection par le virus de l'hépatite C aggrave-t-elle le pronostic des patients infectés par le VIH?

La revue de medecine interne, 1997-05, Vol.18, p.s154-s154

1997

Volltextzugriff (PDF)

Risk factors of HIV-seropositive subjects detected through blood donation in France, 1985-1988

Transfusion (Philadelphia, Pa.), 1989-01, Vol.29 (1), p.84-86

1989

Volltextzugriff (PDF)

Rapid progression of HIV infection in HBeAg-positive patients

Journal of acquired immune deficiency syndromes and human retrovirology, 1998-10, Vol.19 (2), p.198-200

1998

Volltextzugriff (PDF)

Survival After AIDS-Defining Events in Patients With<200 Lymphocytes CD4+ × 106/L Who Are Toxoplasmosis Antibody Positive

Journal of acquired immune deficiency syndromes and human retrovirology, 1997-04, Vol.14 (5), p.459-464

1997

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(22)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Infectious Diseases
(15)
Humans
(13)
Immunology
(13)
Male
(12)
Female
(11)
Adult
(10)
Biological And Medical Sciences
(8)
Hiv Infections - Drug Therapy
(8)
Medical Sciences
(8)
Human Immunodeficiency Virus
(7)
Middle Aged
(7)
Aids/hiv
(6)
Hiv
(6)
Treatment Outcome
(6)
Viral Load
(6)
Immunodeficiencies
(5)
Immunodeficiencies. Immunoglobulinopathies
(5)
Immunopathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reinforcement of hydrated portland cement with high molecular mass water-soluble polymers

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co‐infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End‐Stage Liver Disease as Compared to HCV Mono‐infected Patients

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 Study

Prognostic factors of survival in HIV/HCV co‐infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial

Toxoplasmic Encephalitis in Patients with the Acquired Immunodeficiency Syndrome

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients

Increased Risk of Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients with Pyrimethamine-Related Rash

Pyrimethamine for Primary Prophylaxis of Toxoplasmic Encephalitis in Patients with Human Immunodeficiency Virus Infection: A Double-Blind, Randomized Trial

Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients

Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039

Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data

La co-infection par le virus de l'hépatite C aggrave-t-elle le pronostic des patients infectés par le VIH?

Risk factors of HIV-seropositive subjects detected through blood donation in France, 1985-1988

Rapid progression of HIV infection in HBeAg-positive patients

Survival After AIDS-Defining Events in Patients With<200 Lymphocytes CD4+ × 106/L Who Are Toxoplasmosis Antibody Positive

Suchergebnisse filtern